Fig. 4. Schematic diagram representing the experimental design of (A) crypto targeted 906 ester loaded PLGA nanoparticles, (B) in vitro evaluation, (C) nanoparticles packing in capsules, (D) enteric coating of capsules, (E) oral delivery of nanoparticle carrying capsules in the mouse model and anticryptosporidial activity testing.